购物车
全部删除
您的购物车当前为空
别名 DCC-2701
Altiratinib (DCC-2701) 是一种多靶点激酶抑制剂,能够抑制 MET (IC50:2.7 nM),TIE2 (IC50:8 nM),VEGFR2 (IC50:9.2 nM),FLT3 (IC50:9.3 nM),Trk1 (IC50:0.85 nM),Trk2 (IC50:4.6 nM) 和 Trk3 (IC50:0.83 nM)。


为众多的药物研发团队赋能,
让新药发现更简单!
Altiratinib (DCC-2701) 是一种多靶点激酶抑制剂,能够抑制 MET (IC50:2.7 nM),TIE2 (IC50:8 nM),VEGFR2 (IC50:9.2 nM),FLT3 (IC50:9.3 nM),Trk1 (IC50:0.85 nM),Trk2 (IC50:4.6 nM) 和 Trk3 (IC50:0.83 nM)。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 176 | 现货 | |
| 5 mg | ¥ 455 | 现货 | |
| 10 mg | ¥ 747 | 现货 | |
| 25 mg | ¥ 1,280 | 现货 | |
| 50 mg | ¥ 1,980 | 现货 | |
| 100 mg | ¥ 3,730 | 现货 | |
| 500 mg | ¥ 7,880 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 513 | 现货 |
Altiratinib 相关产品
| 产品描述 | Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with an HGF antagonist in vitro. |
| 靶点活性 | FLT3:9.3 nM, MET (Y1230C):0.37 nM, MET (Y1230C):1.2 nM, MET (D1228N):1.3 nM, VEGFR2:9.2 nM, TrkA:0.85 nM, Trk2:4.6 nM, Trk3:0.93 nM, TrkC:0.85 nM, Tie2:8 nM |
| 别名 | DCC-2701 |
| 分子量 | 510.46 |
| 分子式 | C26H21F3N4O4 |
| CAS No. | 1345847-93-9 |
| Smiles | Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1 |
| 密度 | 1.557 g/cm3 (Predicted) |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 240 mg/mL (470.16 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.92 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容